Publication

Durable responses from acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) as first line therapy for patients with diffuse large B-cell lymphoma (DLBCL): the Accept Phase Ib/II Single Arm Study

Davies, A. J.
; 
Caddy, J.
; 
McLaughlin, K.
; 
Wignall, C.
; 
Waugh, R.
; 
Collins, G. P.
; 
Stanton, L.
; 
Saunders, G. N.
; 
Cummin, T.
; 
Schuh, A.
... show 9 more
Citations
Altmetric:
Abstract
Authors
Davies, A. J.
Caddy, J.
McLaughlin, K.
Wignall, C.
Waugh, R.
Collins, G. P.
Stanton, L.
Saunders, G. N.
Cummin, T.
Schuh, A.
Ardeshna, K. M.
McMillan, A. K.
Radford, John A
Lewis, D. J.
Coleman, A. R.
Griffiths, G.
Burton, C.
Barrans, S.
Johnson, P.
Affiliation
Cancer Research UK Experimental Cancer Medicines Centre UK, Southampton,
Description
Date
2022
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Type
Meetings and Proceedings
Citation
Davies AJ, Caddy J, McLaughlin K, Wignall C, Waugh R, Collins GP, et al. Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study. Blood. 2022 Nov;140:9478-9. PubMed PMID: WOS:000893230302210.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/626204
Embedded videos